Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REN-1654 in Post-Herpetic Neuralgia
NCT00099528Phase 2Unknown
- Sponsor
- Renovis
- Start
- Aug 2003
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of REN-1654 in postherpetic neuralgia (PHN) (3 arms), sponsored by Renovis. Primary endpoint: Change from baseline of the Daily Spontaneous Pain Rating in the most painful area at 3 weeks. Status: unknown.
02
Drugs
REN-1654
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00099528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099528.